We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Novavax (NVAX) Outpaces Stock Market Gains: What You Should Know
Read MoreHide Full Article
Novavax (NVAX - Free Report) closed at $0.59 in the latest trading session, marking a +1.57% move from the prior day. The stock outpaced the S&P 500's daily gain of 0.46%. At the same time, the Dow added 0.15%, and the tech-heavy Nasdaq gained 0.59%.
Coming into today, shares of the vaccine maker had gained 5.14% in the past month. In that same time, the Medical sector gained 0.72%, while the S&P 500 gained 3.24%.
Wall Street will be looking for positivity from NVAX as it approaches its next earnings report date. The company is expected to report EPS of -$0.12, up 14.29% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $4.80 million, down 50.26% from the prior-year quarter.
NVAX's full-year Zacks Consensus Estimates are calling for earnings of -$0.39 per share and revenue of $11.45 million. These results would represent year-over-year changes of +22% and -66.61%, respectively.
It is also important to note the recent changes to analyst estimates for NVAX. These revisions help to show the ever-changing nature of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 9.69% higher within the past month. NVAX currently has a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 78, which puts it in the top 31% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Novavax (NVAX) Outpaces Stock Market Gains: What You Should Know
Novavax (NVAX - Free Report) closed at $0.59 in the latest trading session, marking a +1.57% move from the prior day. The stock outpaced the S&P 500's daily gain of 0.46%. At the same time, the Dow added 0.15%, and the tech-heavy Nasdaq gained 0.59%.
Coming into today, shares of the vaccine maker had gained 5.14% in the past month. In that same time, the Medical sector gained 0.72%, while the S&P 500 gained 3.24%.
Wall Street will be looking for positivity from NVAX as it approaches its next earnings report date. The company is expected to report EPS of -$0.12, up 14.29% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $4.80 million, down 50.26% from the prior-year quarter.
NVAX's full-year Zacks Consensus Estimates are calling for earnings of -$0.39 per share and revenue of $11.45 million. These results would represent year-over-year changes of +22% and -66.61%, respectively.
It is also important to note the recent changes to analyst estimates for NVAX. These revisions help to show the ever-changing nature of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 9.69% higher within the past month. NVAX currently has a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 78, which puts it in the top 31% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions.